NCT05564650 2025-12-08
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Thomas Jefferson University
Phase 1 Active not recruiting
Thomas Jefferson University
Chinese PLA General Hospital
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.